340B Drug Discount Program At-A-Glance

For the 340B Drug Discount Program to work properly and benefit low-income patients, reforms are needed. Our latest infographic shows why.

VIEW DETAILS

Total Discounted Purchases Made under the 340B Drug Pricing Program, 2007-2016

Since its inception, the 340B program has grown dramatically. Currently, about 45% of all Medicare acute care hospitals participate in the program, and between 2014-2016, the volume of purchases made through 340B more than doubled, expanding 125%.

VIEW DETAILS

340B Drug Purchases as Percentage of Total U.S. Drug Market, 2007-2016

Despite this uptick in 340B sales, evidence suggests that certain hospitals are not passing on the savings associated with sales from the program to patients in the form of financial or co-pay assistance.

VIEW DETAILS

What the Experts Say on 340B

The 340B program has expanded well past the intent of Congress, and patients may not be seeing the benefits they deserve.

VIEW DETAILS

What Experts Are Saying about 340B

There is growing evidence that hospitals are pocketing the savings from 340B payments and not passing them on to the patients who need them.

VIEW DETAILS

Median Change in Charity Care Level (2013-2015)

Despite staggering growth in the number of hospitals - and volume of purchases - made under the program, 340B hospitals have demonstrated a dramatic decline in charity care provided since 2013. This raises questions about who is benefiting from 340B - patients or hospitals.

VIEW DETAILS